Home Newsfeeds Surmodics Sees FY23 Adj EPS Of $(2.54)-$(2.14) vs. Consensus of $(1.23)

Surmodics Sees FY23 Adj EPS Of $(2.54)-$(2.14) vs. Consensus of $(1.23)

Expects the fiscal year 2023 total revenue of $103 million – $107 million versus the consensus of $99.76 million

byBenzinga Newsdesk

November 9, 2022

1 minute read

Expects the fiscal year 2023 total revenue of $103 million – $107 million versus the consensus of $99.76 million

JP Morgan Maintains Neutral on Wolfspeed, Raises Price Target to $130

By Benzinga Newsdesk

October 10, 8:57 AM

JP Morgan analyst Samik Chatterjee maintains Wolfspeed (NYSE:WOLF) with a Neutral and raises the price target from $120 to $130.

WOLF

Coinbase CEO’s War Cry After SEC Sues Crypto Exchange: ‘We’ll Get The Job Done’

By Murtuza Merchant

June 6, 3:45 PM

Coinbase (NASDAQ: COIN) CEO Brian Armstrong is holding firm Tuesday in a legal battle with the Securities and Exchange Commission expressing his determination to "get the job done"

COIN

Sensei Biotherapeutics Presents New Preclinical Data On SNS-103 Targeting ENTPDase1 (CD39) At The American Association For Cancer Research Annual Meeting 2023

By Happy Mohamed

April 18, 4:16 PM

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103

SNSE

DoorDash, Wynn Resorts And 2 Other Stocks Insiders Are Selling

By Avi Kapoor

May 29, 8:21 AM

The Nasdaq 100 closed higher by around 0.3% on Tuesday. Investors, meanwhile, focused on some notable insider trades.…

DASH

Surmodics Sees FY23 Adj EPS Of $(2.54)-$(2.14) vs. Consensus of $(1.23)

Related Posts

JP Morgan Maintains Neutral on Wolfspeed, Raises Price Target to $130

Coinbase CEO’s War Cry After SEC Sues Crypto Exchange: ‘We’ll Get The Job Done’

Sensei Biotherapeutics Presents New Preclinical Data On SNS-103 Targeting ENTPDase1 (CD39) At The American Association For Cancer Research Annual Meeting 2023

DoorDash, Wynn Resorts And 2 Other Stocks Insiders Are Selling